Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$48.94 USD
-0.81 (-1.63%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $48.92 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
KYMR 48.94 -0.81(-1.63%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYMR
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
Other News for KYMR
Boeing's Starliner to return without astronauts: Morning Buzz
Kymera upgraded, MoonLake downgraded: Wall Street's top analyst calls
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wolfe upgrades Kymera Therapeutics, calls 'great long-term trade'
Wolfe Research gets more bullish on Kymera Therapeutics, upgrades shares